IFNA1 and neoplasm: These findings suggest that while HDAC inhibitors hold substantial promise in activating IFN pathways and reprogramming the tumor immune microenvironment, their clinical efficacy remains constrained by tumor heterogeneity, immune evasion strategies, and compensatory immunosuppressive mechanisms.